Exercise of Warrants
ValiRx PLC has announced the exercise of warrants for 80,000 ordinary shares at 0.5 pence per share, generating gross proceeds of £400. These new ordinary shares will be admitted to trading on AIM around January 23, 2026, and will rank pari passu with existing shares. Following this issuance, the company's enlarged issued share capital will consist of 742,801,072 ordinary shares.
Select text to share a quote on X · sign in to keep highlights & notes in your VAL notes
ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health announces it has received notification for the exercise of warrants over 80,000 ordinary shares in the Company at an exercise price of 0.5 pence per share providing the Company with gross proceeds of £400 ("Warrant Exercise").
Application will be made to the London Stock Exchange to admit the 80,000 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 23 January 2026. The new ordinary shares will rank pari passu with the existing ordinary shares.
For the purposes of the Disclosure and Transparency Rules, following the issue of shares detailed above as a result of the Warrant Exercise, the enlarged issued share capital of the Company will comprise 742,801,072 ordinary shares of 0.1 pence each. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.
| Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub | https://valirx.com/link/exkQJy |
| ValiRx plc Dr Mark Eccleston, CEO | Tel: +44 115 784 0025 www.valirx.com Mark.Eccleston@valirx.com |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti | Tel: +44 (0) 20 7213 0880 |
| Shard Capital Partners LLP (Sole Broker) Damon Heath | Tel: +44 (0) 20 7186 9000 |
| V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director | +44 (0) 115 787 0206 www.vformation.biz lucy@vformation.biz sue@vformation.biz |
Subscribe to our news alert service: https://valirx.com/s/f298d1
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.